Form 4: Xencor Director Kurt A. Gustafson Reports Stock and Option Transactions

Director Kurt A. Gustafson reports acquisition of restricted stock units and stock options in Xencor Inc.

Summary

• On June 13, 2024, Kurt A. Gustafson, a director of Xencor Inc., reported transactions involving the company's stock.
• Gustafson acquired 5,986 shares of common stock and disposed of 11,993 shares.
• He also acquired options to purchase 11,971 shares of common stock at an exercise price of $21.31, expiring on June 12, 2034.
• The restricted stock units will fully vest on the first anniversary of the grant date.
• The stock options will vest in equal monthly installments over one year, becoming fully vested on June 13, 2025.
• Following these transactions, Gustafson directly owns 11,971 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing primarily reflects routine transactions. The acquisition of stock and options is mildly positive, while the disposal of shares is mildly negative. Overall, the impact is balanced.

Positives

• Acquisition of restricted stock units and stock options by a director signals confidence in the company's future performance.

Negatives

• The disposal of 11,993 shares of common stock could be interpreted negatively, although it may be part of a planned diversification strategy.

Risks

• The vesting schedule of the stock options and restricted stock units could influence the director's decisions regarding their holdings in the short term.
• Market fluctuations could impact the value of the acquired stock and options.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of the stock options and restricted stock units suggest a long-term commitment from the director.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key personnel.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• Vesting schedules of one year for restricted stock units and monthly vesting over one year for stock options are fairly standard practices.
• Comparing the size of the grant to those of directors at comparable companies like Amgen, Regeneron, or Gilead would provide further context.

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment, depending on how investors interpret the director's actions.
• Employees may view the stock and option grants as a positive sign of the company's commitment to its leadership.

Key Dates